Bell Investment Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Bell Investment Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,070	Closed	-$2.92K	–	1906
2025 Q4	$2.92K	Buy	+1,070	New	+$2.48K	﹤0.01%	1210
2025 Q2	–	Sell	-43	Closed	-$144	–	1934
2025 Q1	$144	Sell	43 -64	-60%	-$330	﹤0.01%	1880
2024 Q4	$792	Hold	107	–	–	﹤0.01%	1654
2024 Q3	$1K	Buy	107 +64	+149%	+$606	﹤0.01%	1588
2024 Q2	$345	Buy	+43	New	+$461	﹤0.01%	1890
2023 Q4	–	Sell	-63	Closed	-$287	–	1956
2023 Q3	$287	Hold	63	–	–	﹤0.01%	1892
2023 Q2	$444	Buy	+63	New	+$451	﹤0.01%	1879
2022 Q4	–	Sell	-51	Closed	–	–	1981
2022 Q3	$0	Hold	51	–	–	﹤0.01%	1826
2022 Q2	$1K	Buy	+51	New	+$668	﹤0.01%	1464
2021 Q4	$2K	Buy	121 +82	+210%	+$1.8K	﹤0.01%	1158
2021 Q3	$1K	Buy	+39	New	+$919	﹤0.01%	1419

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Bell Investment Advisors's IOVA Position: Q1 2026 in Review

Bell Investment Advisors sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 1,070 shares — an estimated $2.92K sold.

Bell Investment Advisors first reported a position in IOVA in Q3 2021 and held it in 11 quarters. The position peaked at $2.92K in Q4 2025. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Bell Investment Advisors reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
Bell Investment Advisors sold 1,070 Iovance Biotherapeutics shares in Q1 2026, an estimated $2.92K.
Bell Investment Advisors first reported a position in Iovance Biotherapeutics in Q3 2021 and held it in 11 quarters.
Bell Investment Advisors's Iovance Biotherapeutics position peaked at $2.92K in Q4 2025.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Bell Investment Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.